Emalex Biosciences is a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders with limited or no treatment options. Aligned with its mission, the company is evaluating treatments for childhood-onset fluency disorder(stuttering), and for children and adolescents with Tourette syndrome.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/23/21	$35,000,000	Series C	Fidelity Management & Research Company Paragon Biosciences Valor Equity Partners	undisclosed
11/03/22	$250,000,000	Series D	Bain Capital Life Sciences Fidelity Management & Research Company Paragon Biosciences Valor Equity Partners	undisclosed